NVP-AAD777 is a selective VEGFR-2 inhibitor with potential therapeutic utility in treating diseases associated with aberrant VEGFR-2 signaling; it effectively inhibits phosphorylation of VEGFR-2 (Tyr1175) in rat lung tissue without causing emphysematous changes in the lungs, even when combined with cigarette smoke exposure.